Aim for this study is to measure the prevalence of Gestational Diabetes Mellitus (GDM) using World Health Organisation (WHO) versus International Association of Diabetes in Pregnancy Study Group (IADPSG) criteria among pregnant mother in Universiti Kebangsaan Malaysia Medical Centre (UKMMC)
It will then be used to measure the incidence of adverse maternal and neonatal outcomes in women diagnosed with GDM using either of the criteria. Patients with risk factors for GDM will be recruited and randomised to either group once fulfilled the inclusion and exclusion criteria and agreed to join this study. Subjects will then undergo 75g oral glucose tolerance test and diagnosis will be established based on the group assigned.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
506
Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
Obstetrics & Gynaecology Department, National University of Malaysia
Cheras, Kuala Lumpur, Malaysia
RECRUITINGTo measure the prevalence of GDM diagnosed using WHO versus IADPSG criteria
Prevalence of GDM will be reported in percentage for both groups- WHO and IADPSG
Time frame: 14-37weeks
To measure the incidence of adverse maternal outcomes in women diagnosed with GDM using either of the criteria (WHO or IADPSG)
Number of incidence in each group will be reported in percentage: Primary caesarean section
Time frame: 14-37 weeks
To measure the incidence of adverse maternal outcomes in women diagnosed with GDM using either of the criteria (WHO or IADPSG)
Number of incidence in each group will be reported in percentage: Gestational hypertension or pre-eclampsia
Time frame: 14-37 weeks
To measure the incidence of adverse maternal outcomes in women diagnosed with GDM using either of the criteria (WHO or IADPSG)
Number of incidence in each group will be reported in percentage: Preterm delivery (\<37 weeks gestation)
Time frame: 14-37 weeks
To measure the incidence of adverse neonatal outcomes in women diagnosed with GDM using either of the criteria (WHO or IADPSG)
Number of incidence will be reported in percentage: Macrosomia (BW\>90th centile for gestational age, gender and ethnicity)
Time frame: 14-37 weeks
To measure the incidence of adverse neonatal outcomes in women diagnosed with GDM using either of the criteria (WHO or IADPSG)
Number of incidence will be reported in percentage: Neonatal hypoglycaemia
Time frame: 14-37 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
To measure the incidence of adverse neonatal outcomes in women diagnosed with GDM using either of the criteria (WHO or IADPSG)
Number of incidence will be reported in percentage: Shoulder dystocia or birth injury
Time frame: 14-37 weeks